Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR T-Cell Therapy for Relapsed/Refractory Immune Thrombocytopenia
NCT05315778Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-BCMA CAR T cells in immune thrombocytopenia (ITP), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
autologous anti-BCMA CAR T cells
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05315778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315778.